Novartis AG (NVS) Receives Buy Rating from JPMorgan Chase & Co.
A number of other research firms have also weighed in on NVS. Zacks Investment Research lowered Novartis AG from a hold rating to a sell rating in a research report on Tuesday, May 17th. Citigroup Inc. reiterated a neutral rating on shares of Novartis AG in a research report on Wednesday, May 18th. Bank of America Corp. reiterated a hold rating on shares of Novartis AG in a research report on Wednesday, May 18th. TheStreet upgraded Novartis AG from a hold rating to a buy rating in a research report on Friday, June 24th. Finally, Argus reiterated a hold rating on shares of Novartis AG in a research report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $91.20.
Novartis AG (NYSE:NVS) opened at 79.34 on Tuesday. The stock’s 50 day moving average is $81.17 and its 200-day moving average is $78.07. Novartis AG has a 1-year low of $69.90 and a 1-year high of $98.95. The firm has a market cap of $188.93 billion, a P/E ratio of 28.33 and a beta of 0.58.
Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.05. Novartis AG had a return on equity of 15.33% and a net margin of 13.84%. The business earned $12.47 billion during the quarter, compared to analysts’ expectations of $12.33 billion. During the same quarter last year, the business posted $1.25 earnings per share. Analysts forecast that Novartis AG will post $4.73 EPS for the current year.
Several large investors have recently bought and sold shares of NVS. Integrated Investment Consultants LLC increased its stake in Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares during the period. Whitnell & Co. increased its stake in Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares during the period. Iowa State Bank purchased a new stake in Novartis AG during the second quarter worth $122,000. M&R Capital Management Inc. purchased a new stake in Novartis AG during the second quarter worth $122,000. Finally, WFG Advisors LP increased its stake in Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares during the period. 9.78% of the stock is owned by institutional investors.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.